Table 1.
Patient characteristics
| Demographic Covariates Categorical | n (%) | |
| Tumor Type | ||
| NSCLC all types | 158 (71.5) | |
| Non-Squamous | 96 | |
| Squamous | 42 | |
| Unknown NSCLC type | 20 | |
| Melanoma | 48 (21.7) | |
| RCC | 14 (6.3) | |
| Mesothelioma | 1 (0.5) | |
| Treatment | ||
| Nivolumab monotherapy (3 mg/kg Q2W) | 221 (100) | |
| Gender | ||
| Male | 138 (62.4) | |
| Female | 83 (37.6) | |
| Race | ||
| Caucasian | 195 (88.2) | |
| Other | 5 (2.3) | |
| Unknown | 21 (9.5) | |
| WHO Performance Status | ||
| 0 | 63 (28.5) | |
| 1 | 103 (46.6) | |
| 2 | 4 (1.8) | |
| Unknown | 51 (23.1) | |
| Weight loss prior to start therapy (only in NSCLC) | ||
| Yes | 36 (16.3) | |
| No | 81 (36.7) | |
| Unknown | 104 (47.1) | |
| Demographic and Laboratory Covariates Continuous | Median (IQR) | n (%) |
| Age (yr) | 65 (59–71) | 221 (100) |
| Body Weight (kg) | 78.5 (70–88) | 220 (99.5) |
| Body Surface Area (m2) | 1.95 (1.81–2.09) | 205 (93) |
| Tumor Burden 3D (cm3; only in NSCLC) | 18.6 (66–98) | 25 (11) |
| Creatinine (μmol/L) | 81 (66–98) | 203 (92) |
| CKD (mL/min) | 81 (62–90) | 203 (92) |
| Total Protein (g/L) | 73 (69–90) | 163 (74) |
| Albumin (g/L) | 42 (42–45) | 174 (79) |
| LD (U/L) | 215 (183–275) | 196 (89) |
| Leucocytes (109 cells/L) | 7.7 (6.3–10.2) | 203 (92) |
Baseline covariates of patients
Abbreviations: n number of patients, IQR inter-quartile range, CKD CKD-EPI renal clearance, LD lactate dehydrogenase